SP100 and prostate cancer: We find that SP100 and TGFB3 occupy alterative positions in low Gleason score cancers compared to higher Gleason scored cancers, and that LMNA repositions more internally in many non-metastatic and low risk prostate cancers, but infrequently reposition in high risk/aggressive cancers.